Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Opioid analgesic which is used for treatment of chronic pain.
At latest update, relevant data on its excretion into breast milk were not found.
Despite of a low molecular weight and a low serum-protein binding capacity that would favor excretion into the milk, its high value of volume distribution would permit a shorter permanence in the blood that would hamper its excretion.
A low oral bioavailability would hamper absorption from ingested mother's milk, except among newborn infants o prematures, who may attain an increased absorption capacity.
The risk for the infants would be minimized if the breast feed is avoided within 1 to 4 hours (non-depot formulation), or, within 3 to 6 hours (depot formulation) after taking medication.
Until more information on this drug is available, other options that are known to be safer are recommended, especially when the baby is a newborn or a premature.
Follow-up of symptoms as sedation or gastrointestinal disorders is recommended.